Astrana Health, Inc. (NASDAQ:ASTH) Shares Sold by Point72 DIFC Ltd

Point72 DIFC Ltd lessened its stake in Astrana Health, Inc. (NASDAQ:ASTH) by 36.6% during the third quarter, Holdings Channel reports. The firm owned 1,201 shares of the company’s stock after selling 692 shares during the period. Point72 DIFC Ltd’s holdings in Astrana Health were worth $70,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ASTH. Royce & Associates LP acquired a new position in Astrana Health in the third quarter valued at $6,661,000. Amalgamated Bank purchased a new position in shares of Astrana Health in the 3rd quarter worth about $713,000. Principal Financial Group Inc. acquired a new position in shares of Astrana Health in the 3rd quarter valued at about $13,383,000. Diamond Hill Capital Management Inc. purchased a new stake in shares of Astrana Health during the 3rd quarter worth about $8,245,000. Finally, Summit Global Investments acquired a new stake in Astrana Health during the 3rd quarter worth approximately $753,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on ASTH. BTIG Research lifted their price target on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. TD Cowen started coverage on shares of Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 target price on the stock. KeyCorp initiated coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating for the company. Finally, Robert W. Baird boosted their price objective on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $65.17.

Astrana Health Stock Performance

Astrana Health stock opened at $40.01 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The firm’s fifty day moving average price is $51.13 and its 200 day moving average price is $48.19. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 30.78, a price-to-earnings-growth ratio of 1.94 and a beta of 1.14. Astrana Health, Inc. has a 12-month low of $32.32 and a 12-month high of $63.20.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. The business had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period in the previous year, the company earned $0.47 earnings per share. On average, research analysts forecast that Astrana Health, Inc. will post 1.16 EPS for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.